Navigation Links
Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China
Date:1/3/2012

PALO ALTO, Calif., Jan. 3, 2012 /PRNewswire/ -- Vivo Ventures, a healthcare investment firm with offices in Palo Alto, California, Shanghai, and Chengdu, China, announced the final closing of Vivo Ventures VII ("Vivo VII") at $375 million, which brings the firm's total funds under management to more than $1 billion.

Vivo plans to invest the capital primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China.  As an early entrant to the Chinese healthcare market, Vivo plans to continue assisting companies in both countries in their efforts to forge cross-border partnerships, enabling companies to acquire new products and expand the market for their existing products.  Vivo also intends to continue its successful strategies of building companies from scratch, identifying later stage products with a high probability of FDA approval, and investing directly in public companies.

Vivo's recent IPOs and exits include Sagent (IPO, Nasdaq), China Kanghui (IPO, NYSE), Vicept (acquired by Allergan), Bioform (acquired by Merz), as well as investments in Avanir Pharmaceuticals (Nasdaq), Acura Pharmaceuticals (Nasdaq), Lee's Pharm (HKEx), and Achillion Pharmaceuticals (Nasdaq).

The managing partners of Vivo VII are Drs. Frank Kung, Albert Cha, Edgar Engleman, Chen Yu, and James Zhao. Investors in the Vivo VII include pension funds, funds of funds, university endowments, foundations, financial institutions, and family offices. In addition to limited partners that participated in Vivo's earlier funds, Vivo VII added a number of new institutional investors from the U.S., Europe, and Asia.

About Vivo Ventures

Founded in 1996, Vivo Ventures is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China.  With more than $1 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising later development stage products in the U.S. and revenue stage companies in China.   Vivo Ventures (http://www.vivoventures.com) has offices in Palo Alto, California, Shanghai, China, and Chengdu, China. 

 

 


'/>"/>
SOURCE Vivo Ventures, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Diagnostic Imaging Companies M&A, Joint Ventures, R&D Pipeline, and Strategies
2. PharmaSecure, an Innovator in Pharmaceutical Serialization, Closes $3.9M Investment by Eric Schmidts Innovation Endeavors, Gray Ghost Ventures, Healthtech Capital and the TEEC Angel Fund
3. USRBC President Ed Verona Lauds GE Announcement on Energy and Healthcare Joint Ventures in Russia
4. Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures"
5. Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Global Health Ventures to Present Live, Online at RetailInvestorConferences.com on August 4th
7. PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine
8. Vivo Ventures Announces Promotions of Dr. Chen Yu and Dr. James Zhao to Managing Partner
9. XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System
10. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
11. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
Breaking Medicine News(10 mins):